NCT01300026 - AMG 319 Lymphoid Malignancy FIH | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

December 31, 2016

Conditions

CancerChronic Lymphocytic LeukemiaDiffuse Large Cell LymphomaHematologic MalignanciesHematologyLeukemiaLow Grade LymphomaLymphomaMantle Cell LymphomaNon-Hodgkin's LymphomaOncologyOncology PatientsT Cell LymphomaTumors

Interventions

DRUG

AMG 319

AMG 319 is a highly selective, orally bioavailable and potent small molecule inhibitor of PI3Kδ.

Trial Locations (3)

27710

Research Site, Durham

84112

Research Site, Salt Lake City

07601

Research Site, Hackensack